Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : COVID SCIENCE-Statins may slightly lower COVID-19 death risk; using a different vaccine as booster may offer more protection

10/15/2021 | 02:13pm EST

Oct 15 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Statins may protect slightly against COVID-19 death

Widely-used statin drugs for lowering cholesterol may be linked to a slightly lower risk of dying from COVID-19, new data suggest. Researchers at Karolinska Institute in Sweden reviewed the medical records of nearly 1 million residents of Stockholm over the age of 45 between March and November 2020, roughly 18% of whom had been prescribed a statin, such as Pfizer Inc's Lipitor (atorvastatin) and Merck & Co's Zocor (simvastatin). The people prescribed statins had more risk factors for poor COVID-19 outcomes: they were older, more often male, had more medical conditions, lower education levels and less disposable income. After taking all that into account, statin users were still 12% less likely to have died of COVID-19 during the study period, according to a report published on Thursday in PLOS Medicine https://bit.ly/3aGoNE1. The researchers did not compare outcomes in people who actually got infected with the virus, however. And they only had data on prescriptions - not on whether patients took the medicine as prescribed. A formal clinical trial would be needed to confirm the findings. Still, they conclude, their data "suggest that statin treatment may have a modest preventive therapeutic effect on COVID-19 mortality."

Boosting with a different vaccine is safe, may be better

People who got Johnson & Johnson's COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from either Pfizer Inc/BioNTech SE or Moderna Inc, according to a study run by the National Institutes of Health. The trial, which included more than 450 adults who received initial shots from Pfizer/BioNTech, Moderna, or J&J, also showed that "mixing and matching" booster shots using different vaccine technology is safe in adults, the researchers reported in a paper posted on medRxiv on Wednesday https://bit.ly/2YKYwBN ahead of peer review. Moderna's and Pfizer's vaccines are based on messenger RNA (mRNA) while J&J's uses viral vector technology. The trial looked at a total of nine combinations of initial shots and boosters. Using different types of shots as boosters generally produced a comparable or higher antibody response than using the same type, the researchers reported. Mixing booster doses "may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines," they said.

Old age alone does not predict COVID-19 mortality risk

Older patients are known to be at higher risk for poor outcomes after infection with the coronavirus, but among those hospitalized with COVID-19, other characteristics help predict who is likely to do poorly, new data suggest. In a review of data on 4,783 people age 65 and older who were hospitalized for COVID-19 early in the pandemic, researchers at Northwell Health hospitals in New York found that age itself did not independently predict whether a patient was more likely to die. Instead, they reported on Thursday in BMC Geriatrics https://bit.ly/3AIFkSv, more important predictors of death for elderly patients were factors such as how independent they were before the infection, how sick they were when they arrived at the hospital, and their pre-existing medical conditions, such as high blood pressure, kidney disease, lung disease and dementia. The researchers noted that in facilities forced to ration care or facing resource shortages, some guidelines use advanced age as a reason to deny care. "Our findings support the American Geriatrics Society position statement indicating age alone should never be used to make decisions regarding resource allocation under conditions of resource scarcity," the researchers said. "Although age is still an important factor in the overall risk of COVID-19 mortality... a comprehensive approach that accounts for the above factors is essential in preventing ageism."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

(Reporting by Nancy Lapid and Carl O'Donnell; Editing by Bill Berkrot)


ę Reuters 2021
All news about MODERNA, INC.
05:10aHARVARD UNIVERSITY : Moderna edges out Pfizer vaccine in head-to-head comparison; Large-sc..
AQ
12:26aModerna To Ready Omicron Booster Shot For US FDA Approval By March 2022
MT
12/01WRAPUP 3-Omicron could be dominant in France within weeks, adviser says
RE
12/01UK Secures 114 Million Additional COVID-19 Shots From Pfizer/BioNTech, Moderna
MT
12/01Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moder..
BU
12/01U.S. administers 462.3 mln doses of COVID-19 vaccines - CDC
RE
12/01UK agrees deals for 114 million more Moderna and Pfizer COVID-19 doses
RE
12/01U.S. CDC Says Administered 462.3 Million Doses Of Covid-19 Vaccine As Of Dec 1
RE
12/01Health Care Tick Lower As Traders Rotate Into Defensive Sectors -- Health Care Roundup
DJ
12/01SOCIAL BUZZ : Apple, Tesla, Alibaba Reign on Wallstreetbets; Moderna, Salesforce, ContextL..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,8x
Yield 2021 -
Capitalization 126 B 126 B -
EV / Sales 2021 6,51x
EV / Sales 2022 5,00x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 310,61 $
Average target price 272,53 $
Spread / Average Target -12,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625
ICON PUBLIC LIMITED COMPANY40.00%22 219